On January 31, the latest news, neurosurgery robot manufacturer Huazhi Weichuang announced the completion of the first round of financing of 50 million yuan, led by Tasly Capital, Huaxing Alpha as the exclusive financial adviser, this round of financing will be used in new product development, Product approval and product sales, product sales and other programs have been comprehensively accelerated. With the deep industrial resources of Tasly, we have accelerated the rapid landing of our products in the country.

It is understood that Huazhi Minimally is the earliest enterprise engaged in the research and development of neurosurgical surgical robots in China. The research and development of surgical robots originally originated from the national “863” project of Tsinghua University, Naval General Hospital and Beijing University of Aeronautics and Astronautics. The results of the transformation, the company now has independent research and development, production and industrialization sales capabilities.

The core product of Huazhi Minimally is the neurosurgical navigation and positioning surgical robot. The robot adopts frameless stereotactic technology, which is mainly used for path planning, surgical navigation and stereotactic in brain surgery. The doctor can determine the location of the patient's lesions through non-invasive conditions through the three-dimensional planning software, and plan the surgical puncture path. The robot accurately locks the surgical puncture position through the navigation and positioning system. Finally, the doctor performs puncture drainage, nuclear damage and other minimally invasive surgery. The average operation time is only 30 minutes, and the surgical positioning accuracy can be less than 1mm. This technology not only reduces the degree of trauma of the patient, but also improves the safety of the operation, greatly reduces the patient's trauma, shortens the operation time and anesthesia time, improves the efficiency of postoperative recovery, and requires no special frame, surgical operation. Convenient and time saving.

The neurosurgical navigation positioning robot is suitable for the treatment of nearly 100 kinds of neurosurgical diseases. It can be supported from routine surgery such as cerebral hemorrhage and biopsy to SEEG and DBS. This product is the only neurosurgery robot in China that has obtained CFDA certification. Nearly 100 hospitals have used and completed tens of thousands of clinical trials after listing, which proves the safety and effectiveness of their products.

In September 2017, Huazhi Microcred became the “brain stereotactic minimally invasive technology training base” approved by the Academic Department of China Medical Education Association. Relying on the platform of the authoritative professional of the Association, the company will rapidly carry out various professional technical trainings for hundreds of thousands of neurosurgeons nationwide, and introduce the non-frame stereotactic minimally invasive technology to more than 3,000 tertiary hospitals nationwide, 14000. Yujia Second Class Hospital and more primary medical institutions.

Wang Zhijun, founder of Huazhi Microcred, said that Huazhi Microcred will focus on prefecture-level hospitals as the main market target, and second and third-tier cities will be the main market, sharing and sinking medical technology to lower-level medical institutions. According to the different needs of tertiary hospitals, secondary hospitals, medical associations and first aid institutions, the company develops corresponding external surgery robot products to meet the needs of different market segments. In addition to neurosurgery, the company plans to apply stereotactic surgical robots to the fields of cardiology, thoracic surgery, hepatobiliary surgery, urology, and dentistry.

At the same time, Wang Rongjun also revealed that Huazhi Microcred has completed three new product technology research and development, and strives to become an international leader in the field of minimally invasive precision medical devices within five years, providing the most valuable products for doctors and patients. Complete neurosurgical solution.

Tiamulin Fumarate Soluble Powder

Tiamulin Powder,Tiamulin Soluble Powder,Tiamulin Hydrogen Fumarate Powder,Tiamulin Animal Drug

Shandong Shengli Bioengineering Co., Ltd , https://www.shenglipharm.com